StockNews.AI
ZVRA
StockNews.AI
105 days

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

1. Zevra will release its Q1 2025 results on May 13, 2025. 2. A conference call will follow the results announcement. 3. Zevra focuses on therapies for rare diseases. 4. Company employs data-driven strategies for drug development. 5. Forward-looking statements signify potential risks and uncertainties.

5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings release may yield mixed investor reactions based on results and forecasts. Historical examples indicate earnings reports can lead to volatility rather than consistent gains.

How important is it?

Earnings reports are crucial for market perception but can be unpredictable. The significance lies in the results' impact on ZVRA's operational capabilities and future growth prospects.

Why Short Term?

The impact from the earnings report is immediate but may not influence long-term trends. Investors often react swiftly to quarterly results, assessing immediate financial health.

Related Companies

N/A
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 May 06, 2025 07:30 ET  | Source: Zevra Therapeutics CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter 2025 on Tuesday, May 13, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at https://investors.zevra.com/. To join via telephone, please use the following dial-in information: (800) 245-3047 (United States)+1 (203) 518-9765 (International)Conference ID: ZVRAQ125 A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page of Zevra’s website at https://investors.zevra.com/. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient need to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. For more information, please visit www.zevra.com or follow us on X and LinkedIn. Caution Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Zevra Contact Nichol Ochsner +1 (732) 754-2545 nochsner@zevra.com  

Related News